J. Lipid Res.  Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bielicki, J. K.
Right arrow Articles by Forte, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bielicki, J. K.
Right arrow Articles by Forte, T. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
The Journal of Lipid Research, Vol. 40, 948-954, May 1999
Copyright © 1999 by Lipid Research, Inc.


Original Article

Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity

John K. Bielickia and Trudy M. Fortea
a Lawrence Berkeley National Laboratory, Life Sciences Division 1-213, University of California at Berkeley, One Cyclotron Road, Berkeley, CA 94720

Correspondence to: John K. Bielicki

The oxidation of low density lipoproteins (LDL) has been implicated in the development of atherosclerosis. Recently, we found that polar lipids isolated from minimally oxidized LDL produced a dramatic inhibition of lecithin: cholesterol acyltransferase (LCAT) activity, suggesting that HDL-cholesterol transport may be impaired during early atherogenesis. In this study, we have identified molecular species of oxidized lipids that are potent inhibitors of LCAT activity. Treatment of LDL with soybean lipoxygenase generated small quantities of lipid hydroperoxides (20 ± 4 nmol/mg LDL protein, n = 3); but when lipoxygenase-treated LDL (1 mg protein/ml) was recombined with the d > 1.063 g/ml fraction of human plasma, LCAT activity was rapidly inhibited (25 ± 4 and 65 ± 16% reductions by 1 and 3 h, respectively). As phospholipid hydroperoxides (PL-OOH) are the principal oxidation products associated with lipoxygenase-treated LDL, we directly tested whether PL-OOH inhibited plasma LCAT activity. Detailed dose–response curves revealed that as little as 0.2 and 1.0 mole % enrichment of plasma with PL-OOH produced 20 and 50% reductions in LCAT activity by 2 h, respectively. To gain insight into the mechanism of LCAT impairment, the enzyme's free cysteines (Cys31 and Cys184) and active site residues were "capped" with the reversible sulfhydryl compound, DTNB, during exposure to either minimally oxidized LDL or PL-OOH. Reversal of the DTNB "cap" after such exposures revealed that the enzyme was completely protected from both sources of peroxidized phospholipids.

We, therefore, conclude that PL-OOH inhibited plasma LCAT activity by modifying the enzyme's free cysteine and/or catalytic residues. These studies are the first to suggest that PL-OOH may accelerate the atherogenic process by impairing LCAT activity.—Bielicki, J. K., and T. M. Forte. Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity. J. Lipid Res. 1999. 40: 948–954.

Supplementary key words: phospholipid hydroperoxides, lecithin:cholesterol acyltransferase, high density lipoproteins, minimally oxidized LDL, atherogenesis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. J. Ng, N. Bourquard, S. Y. Hama, D. Shih, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy
Adenovirus-Mediated Expression of Human Paraoxonase 3 Protects Against the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1368 - 1374.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. E. Moore, M. Navab, J. S. Millar, F. Zimetti, S. Hama, G. H. Rothblat, and D. J. Rader
Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation
Circ. Res., October 14, 2005; 97(8): 763 - 771.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Navab, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, A. C. Wagner, S. Hama, G. Hough, E. Bachini, D. W. Garber, V. K. Mishra, et al.
An Oral ApoJ Peptide Renders HDL Antiinflammatory in Mice and Monkeys and Dramatically Reduces Atherosclerosis in Apolipoprotein E-Null Mice
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1932 - 1937.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. Verreth, D. De Keyzer, M. Pelat, P. Verhamme, J. Ganame, J. K. Bielicki, A. Mertens, R. Quarck, N. Benhabiles, G. Marguerie, et al.
Weight Loss-Associated Induction of Peroxisome Proliferator-Activated Receptor-{alpha} and Peroxisome Proliferator-Activated Receptor-{gamma} Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice
Circulation, November 16, 2004; 110(20): 3259 - 3269.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
P. Holvoet, S. B. Kritchevsky, R. P. Tracy, A. Mertens, S. M. Rubin, J. Butler, B. Goodpaster, and T. B. Harris
The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort
Diabetes, April 1, 2004; 53(4): 1068 - 1073.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
G. A. Kaysen and J. P. Eiserich
The Role of Oxidative Stress-Altered Lipoprotein Structure and Function and Microinflammation on Cardiovascular Risk in Patients with Minor Renal Dysfunction
J. Am. Soc. Nephrol., March 1, 2004; 15(3): 538 - 548.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Mertens, P. Verhamme, J. K. Bielicki, M. C. Phillips, R. Quarck, W. Verreth, D. Stengel, E. Ninio, M. Navab, B. Mackness, et al.
Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice: LCAT Gene Transfer Decreases Atherosclerosis
Circulation, April 1, 2003; 107(12): 1640 - 1646.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. MERTENS and P. HOLVOET
Oxidized LDL and HDL: antagonists in atherothrombosis
FASEB J, October 1, 2001; 15(12): 2073 - 2084.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. J. Brushia, T. M. Forte, M. N. Oda, B. N. La Du, and J. K. Bielicki
Baculovirus-mediated expression and purification of human serum paraoxonase 1A
J. Lipid Res., June 1, 2001; 42(6): 951 - 958.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
W. Khovidhunkit, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld
Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin:cholesterol acyltransferase
J. Lipid Res., June 1, 2001; 42(6): 967 - 975.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. R. McCall, A. C. Carr, T. M. Forte, and B. Frei
LDL Modified by Hypochlorous Acid Is a Potent Inhibitor of Lecithin-Cholesterol Acyltransferase Activity
Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 1040 - 1045.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
W. Pruzanski, E. Stefanski, F. C. de Beer, M. C. de Beer, A. Ravandi, and A. Kuksis
Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins
J. Lipid Res., July 1, 2000; 41(7): 1035 - 1047.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. C. Carr, M. R. McCall, and B. Frei
Oxidation of LDL by Myeloperoxidase and Reactive Nitrogen Species : Reaction Pathways and Antioxidant Protection
Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1716 - 1723.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. H. F. Refsgaard, L. Tsai, and E. R. Stadtman
Modifications of proteins by polyunsaturated fatty acid peroxidation products
PNAS, January 18, 2000; 97(2): 611 - 616.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.